pertuzumab increases 17-aag-induced degradation of erbb2, and this effect is further increased by combining pertuzumab with trastuzumaberbb2 pertuzumab增加17-aag-induced退化,这种效应进一步增加了pertuzumab和曲妥珠单抗结合起来.pdfVIP

下载本文档

3
0
约4.72万字
约 16页
2017-09-11 发布于上海
举报
版权申诉

pertuzumab increases 17-aag-induced degradation of erbb2, and this effect is further increased by combining pertuzumab with trastuzumaberbb2 pertuzumab增加17-aag-induced退化,这种效应进一步增加了pertuzumab和曲妥珠单抗结合起来.pdf

1、本文档共16页，可阅读全部内容。
2、原创力文档（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。
3、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。
5、该文档为VIP文档，如果想要下载，成为VIP会员后，下载免费。
6、成为VIP后，下载本文档将扣除1次下载权益。下载后，不支持退款、换文档。如有疑问请联系我们。
7、成为VIP后，您将拥有八大权益，权益包括：VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
8、VIP文档为合作方或网友上传，每下载1次，网站将根据用户上传文档的质量评分、类型等，对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档

pertuzumab increases 17-aag-induced degradation of erbb2, and this effect is further increased by combining pertuzumab with trastuzumaberbb2 pertuzumab增加17-aag-induced退化,这种效应进一步增加了pertuzumab和曲妥珠单抗结合起来

Pharmaceuticals 2012, 5, 674-689; doi:10.3390/ph5070674 OPEN ACCESS Pharmaceuticals ISSN 1424-8247 /journal/pharmaceuticals Article Pertuzumab Increases 17-AAG-Induced Degradation of ErbB2, and This Effect Is Further Increased by Combining Pertuzumab with Trastuzumab Juliana Bentes Hughes 1, Marianne Skeie Rødland 1, Max Hasmann 2, Inger Helene Madshus 1,3 and Espen Stang 3,* 1 Institute of Pathology, Oslo University Hospital, Rikshospitalet University of Oslo, Oslo 0027, Norway; E-Mails: Juliana.B.Hughes@rr-research.no (J.B.H.); Marianne.S.Rodland@rr-research.no (M.S.R.); Inger.Helene.Madshus@rr-research.no (I.H.M.) 2 Roche Diagnostics GmbH, Pharma Research Penzberg, Nonnenwald 2, Penzberg 82377, Germany; E-Mail: max.hasmann@ (M.H.) 3 Department of Pathology, Oslo University Hospital, Rikshospitalet, Post Box 4950 Nydalen, Oslo 0424, Norway * Author to whom correspondence should be addressed: E-Mail: espsta@rr-research.no; Tel: +47-2307-1483; Fax: +47-2307-1511. Received: 20 April 2012; in revised form: 13 June 2012 / Accepted: 21 June 2012 / Published: 28 June 2012 Abstract: ErbB2 is an important oncogenic protein involved in carcinogenesis of, among others, breast, gastric, and ovarian carcinoma. Over-expression of ErbB2 is found in almost 20% of breast cancers, and this results in proliferative and anti-apoptotic signalling. ErbB2 is therefore an important treatment target. Antibodies recognizing full-length ErbB2 are clinically established, and drugs targeting the ErbB2 stabilizing heat shock protein 90